Research and Clinical Trials

6 vs 12 Treatments of FOLFOX Plus Celecoxib or Placebo for Colon Cancer
Brief Description  
This study is being done to evaluate the effects (good and bad) of an oral drug called celecoxib when given in combination with leucovorin and oxaliplatin (FOLFOX) chemotherapy. Celecoxib is approved by the FDA to treat arthritis. It is also approved to help prevent colon polyps in families with a genetic risk for colon cancer. The addition of celecoxib to FOLFOX chemotherapy is considered investigation.
Who may be Eligible  

  • Histologically documented adenocarcinoma of the colon.
  • Tumors must have been completely resected.
  • At least one pathologically confirmed positive lymph node.
  • No evidence of residual involved lymph node disease or metastatic disease at the time of registration.
  • Patients with synchronous colon cancers are eligible.
  • Patients are ineligible if they use NSAIDs at any dose or aspirin at more than 325 mg at least three times per week, on average.
  • No previous or concurrent malignancy, except treated basal cell or squamous cell cancer of the skin, treated in situ cervical cancer, treated lobular or ductal carcinoma in situ in one breast or any other cancer for which the patient has been disease-free for at least 5 years.
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203